Following patients with clotting and bleeding disorders in China over time
Observes patients with blood clotting and bleeding conditions, tracking their care and outcomes.
Plain-language title generated from the registry record
Registry title: Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Key facts
- Where
- Beijing, Chongqing, and Zhengzhou, ChinaSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study follows people diagnosed with a blood clotting or bleeding disease in China. It collects their medical records and follows them over time.
- Sex
- Everyone can join, women and men.
- Disease stage
- A diagnosed thrombosis (blood clot) or hemostasis (bleeding and clotting) disease.
Main reasons for not taking part
- No long-term follow-up information can be collected, for example if the person cannot be reached or has a serious other disease.
- Alcohol or drug addiction, or mental illness, that affects the ability to follow the study requirements.
- Conditions that the investigator thinks may endanger the person's safety or affect compliance.
Read by machine on 12 November 2026.
Where in China
- Department of Hematology, Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaContact: Zhao WangNot yet recruiting
- Department of Hematology, Beijing HospitalBeijing, ChinaContact: Hui LiuNot yet recruiting
- Peking University Insititute of Hematology, Peking University People's HospitalBeijing, ChinaContact: Xiao Hui Zhang, MDTaking people
- Xinqiao Hospital, Army Military Medical UniversityChongqing, ChinaContact: Xi ZhangNot yet recruiting
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaContact: Zhongxing JiangNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT06727669
- Record updated
- 11 December 2024
- Original description
This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.Read full original descriptionShow less
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Inclusion: Patients who were diagnosed as thrombosis and hemostasis diseases.
Exclusion: Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease; Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements; According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.